Acer Therapeutics Announces Resubmission of New Drug Application for ACER-001 for Treatment of UCDs

Posted: July 19, 2022 at 2:15 am

Acer has notified the FDA in the resubmission that the third-party contract packaging manufacturer is ready for inspection Acer has notified the FDA in the resubmission that the third-party contract packaging manufacturer is ready for inspection

Read more here:
Acer Therapeutics Announces Resubmission of New Drug Application for ACER-001 for Treatment of UCDs

Related Posts